252 related articles for article (PubMed ID: 32118267)
1. Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis.
Hagège B; Tan E; Gayraud M; Fautrel B; Gossec L; Mitrovic S
Rheumatology (Oxford); 2020 Aug; 59(8):1818-1825. PubMed ID: 32118267
[TBL] [Abstract][Full Text] [Related]
2. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
Coates LC; Nash P; Kvien TK; Gossec L; Mease PJ; Rasouliyan L; Pricop L; Jugl SM; Gandhi KK; Gaillez C; Smolen JS
Semin Arthritis Rheum; 2020 Aug; 50(4):709-718. PubMed ID: 32521325
[TBL] [Abstract][Full Text] [Related]
3. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
[TBL] [Abstract][Full Text] [Related]
4. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.
Gorlier C; Orbai AM; Puyraimond-Zemmour D; Coates LC; Kiltz U; Leung YY; Palominos P; Cañete JD; Scrivo R; Balanescu A; Dernis E; Tälli S; Ruyssen-Witrand A; Soubrier M; Aydin SZ; Eder L; Gaydukova I; Lubrano E; Kalyoncu U; Richette P; Husni ME; de Wit M; Smolen JS; Gossec L
Ann Rheum Dis; 2019 Feb; 78(2):201-208. PubMed ID: 30442648
[TBL] [Abstract][Full Text] [Related]
5. Inconsistencies of the Disease Activity Assessment Tools for Psoriatic Arthritis: Challenges to Rheumatologists.
Gezer HH; Duruöz MT; Nas K; Kılıç E; Sargın B; Kasman SA; Alkan H; Şahin N; Cengiz G; Cüzdan N; Gezer İA; Keskin D; Mülkoğlu C; Reşorlu H; Sunar İ; Bal A; Küçükakkaş O; Yurdakul OV; Melikoğlu MA; Baykul M; Ayhan FF; Bodur H; Çalış M; Çapkın E; Devrimsel G; Gök K; Hizmetli S; Kamanlı A; Keskin Y; Ecesoy H; Kutluk Ö; Şen N; Şendur ÖF; Tekeoğlu İ; Tolu S; Toprak M; Tuncer T
Joint Bone Spine; 2022 May; 89(3):105296. PubMed ID: 34656752
[TBL] [Abstract][Full Text] [Related]
6. Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
Wervers K; Vis M; Tchetveriko I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Luime JJ
Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1764-1770. PubMed ID: 29609220
[TBL] [Abstract][Full Text] [Related]
7. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.
Coates LC; Gottlieb AB; Merola JF; Boone C; Szumski A; Chhabra A
J Rheumatol; 2019 Feb; 46(2):160-165. PubMed ID: 30323006
[TBL] [Abstract][Full Text] [Related]
9. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.
Schoels MM; Aletaha D; Alasti F; Smolen JS
Ann Rheum Dis; 2016 May; 75(5):811-8. PubMed ID: 26269398
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
11. Residual Disease Activity and Associated Factors in Psoriatic Arthritis.
Lubrano E; Scriffignano S; Perrotta FM
J Rheumatol; 2020 Oct; 47(10):1490-1495. PubMed ID: 31676704
[TBL] [Abstract][Full Text] [Related]
12. Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis.
Queiro R; Cañete JD; Montilla C; Abad MA; Montoro M; Gómez S; Cábez A;
J Rheumatol; 2019 Jul; 46(7):710-715. PubMed ID: 30709957
[TBL] [Abstract][Full Text] [Related]
13. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.
van Mens LJJ; van de Sande MGH; van Kuijk AWR; Baeten D; Coates LC
Ann Rheum Dis; 2018 Feb; 77(2):251-257. PubMed ID: 29080861
[TBL] [Abstract][Full Text] [Related]
14. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis.
Farkas F; Ikumi N; Elmamoun M; Szentpetery A; FitzGerald O
J Rheumatol; 2021 Aug; 48(8):1272-1278. PubMed ID: 33722944
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices.
Lubrano E; Scriffignano S; Azuaga AB; Ramirez J; Cañete JD; Perrotta FM
RMD Open; 2020 Mar; 6(1):. PubMed ID: 32179713
[TBL] [Abstract][Full Text] [Related]
17. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
[TBL] [Abstract][Full Text] [Related]
18. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
Coates LC; Ritchlin CT; Gossec L; Helliwell PS; Rahman P; Kollmeier AP; Xu XL; Shawi M; Karyekar CS; Contré C; Noël W; Sheng S; Wang Y; Xu S; Mease PJ
Rheumatology (Oxford); 2023 Feb; 62(2):606-616. PubMed ID: 35766811
[TBL] [Abstract][Full Text] [Related]
19. What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?
Coates LC; Lubrano E; Perrotta FM; Emery P; Conaghan PG; Helliwell PS
J Rheumatol; 2019 Jan; 46(1):38-42. PubMed ID: 30219765
[TBL] [Abstract][Full Text] [Related]
20. Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study.
Leung YY; Eder L; Orbai AM; Coates LC; de Wit M; Smolen JS; Kiltz U; Palominos P; Canete JD; Scrivo R; Balanescu A; Dernis E; Meisalu S; Soubrier M; Kalyoncu U; Gossec L
RMD Open; 2023 Sep; 9(3):. PubMed ID: 37709527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]